Leuk Lymphoma. 2013 Sep 27. [Epub ahead of print]

Treatment with cyclophosphamide, vindesine, cytarabine, dexamethasone, and
bleomycin in patients with relapsed/refractory diffuse large B cell lymphoma.

Li M, Li Y, Yin Q, Mi R, Chen L, Du J, Wei X.

Abstract Several chemotherapy regimens have been used as second-line therapies河南省肿瘤医院血液科魏旭东
for relapsed and refractory diffuse large B cell lymphoma (DLBCL); none have
emerged as a preferred regimen. This retrospective study aimed to identify a
regimen with high efficacy and low toxicity for patients with relapsed and
refractory DLBCL. Fifty-eight patients diagnosed with relapsed or refractory
DLBCL were included in the study. Patients were treated with cyclophosphamide,
vindesine, cytarabine, dexamethasone, and bleomycin (COAD-B). The overall
response rate (ORR) was 70.7%, and the median remission duration was 13 months
(3-48 months). The 1-, 2-, and 4-year overall survival rates were 62.4%, 45.7%,
and 34.6%, respectively. The 1-, 2-, and 4-year progression-free survival rates
were 50.0%, 36.7%, and 20.7%, respectively. The responses of patients with
relapsed DLBCL to COAD-B were significantly better than those of patients with
refractory DLBCL (P=0.005). The main adverse reaction of patients was
myelosuppression. Our data indicate that COAD-B should be used in treatment of
patients with relapsed DLBCL.